[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 172, "companyOfficers": [{"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Harry  Shuman", "title": "Chief Accounting Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 58, "title": "CTO & Executive VP", "yearBorn": 1965, "fiscalYear": 2018, "totalPay": 344015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Senior VP", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kathleen  Farren", "title": "IR & Corporate Communications Officer", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander Berthold Hendrik Bakker Ph.D.", "age": 57, "title": "Executive VP, Chief Development Officer & Head of Merus Utrecht", "yearBorn": 1966, "fiscalYear": 2018, "totalPay": 389662, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shannon  Campbell", "title": "Executive VP & Chief Commercial Officer", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ashley  Pereira Pharm.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ernesto  Wasserman M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Van der Touw Noordzij", "title": "Company Secretary", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1546214400, "maxAge": 86400, "priceHint": 2, "previousClose": 40.31, "open": 40.58, "dayLow": 40.01, "dayHigh": 41.54, "regularMarketPreviousClose": 40.31, "regularMarketOpen": 40.58, "regularMarketDayLow": 40.01, "regularMarketDayHigh": 41.54, "beta": 1.105, "forwardPE": -12.477203, "volume": 401089, "regularMarketVolume": 401089, "averageVolume": 576151, "averageVolume10days": 487120, "averageDailyVolume10Day": 487120, "bid": 40.9, "ask": 41.17, "bidSize": 100, "askSize": 100, "marketCap": 2409125888, "fiftyTwoWeekLow": 18.21, "fiftyTwoWeekHigh": 52.035, "priceToSalesTrailing12Months": 54.818893, "fiftyDayAverage": 44.7612, "twoHundredDayAverage": 30.1639, "currency": "USD", "enterpriseValue": 2033689600, "floatShares": 42508127, "sharesOutstanding": 58687600, "sharesShort": 3435876, "sharesShortPriorMonth": 4457568, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0589, "heldPercentInsiders": 0.07181, "heldPercentInstitutions": 0.87357, "shortRatio": 5.26, "shortPercentOfFloat": 0.0591, "impliedSharesOutstanding": 58687600, "bookValue": 6.162, "priceToBook": 6.661798, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -154939008, "trailingEps": -3.0, "forwardEps": -3.29, "enterpriseToRevenue": 46.276, "enterpriseToEbitda": -13.205, "52WeekChange": 0.97736037, "SandP52WeekChange": 0.2160933, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "42321671-9233-3f73-a2ee-487472589127", "messageBoardId": "finmb_24929296", "gmtOffSetMilliseconds": -14400000, "currentPrice": 41.05, "targetHighPrice": 69.0, "targetLowPrice": 52.0, "targetMeanPrice": 60.83, "targetMedianPrice": 61.5, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 354376000, "totalCashPerShare": 6.123, "ebitda": -154007008, "totalDebt": 12162000, "quickRatio": 5.187, "currentRatio": 5.338, "totalRevenue": 43947000, "debtToEquity": 3.413, "revenuePerShare": 0.852, "returnOnAssets": -0.23518999, "returnOnEquity": -0.51355, "freeCashflow": -81108872, "operatingCashflow": -142207008, "revenueGrowth": -0.162, "grossMargins": -2.20063, "operatingMargins": -5.31849, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-18"}]